Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately.

Aaron will be responsible for the management and financial performance of GoodRx’s Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx’s long-term growth strategy and serve as a strategic advisor to the CEO and President, helping to guide the company’s broader vision and business priorities.

Since joining GoodRx in 2020, Aaron has played a pivotal role in building and scaling the business across multiple leadership positions. As Head of Manufacturer Solutions and then Chief Revenue Officer, Aaron helped launch the company’s Pharma Manufacturer Solutions offering and played a key role in growing revenue to $100M+ in just a few years. Prior to GoodRx, he founded ReMy Health, where he developed automation solutions for affordability programs and specialty medication access, and contributed to developing the infrastructure behind the PillPack data network. Earlier in his career, he held leadership roles at Allscripts, where he was responsible for oversight of electronic prescribing, pharma and pharmacy benefits manager (PBM) innovation, and its patient portal business.

Scott will be responsible for all aspects of GoodRx’s relationships with physicians, pharmacists, nurses, and all healthcare professionals, including marketing and product development. This includes pharmacy strategy, clinical engagement, and industry partnerships.

By joining GoodRx, Scott will continue his nearly 30 years of successful service in the U.S. healthcare system. His diverse experience ranges from providing direct patient care to executive level leadership, growing revenue streams, enhancing patient care, scaling infrastructure, and forging industry partnerships for companies including Premier, Inc., Hitachi, In Scope Ventures, and more.

“Our path forward is laser-focused on improving the prescription experience for all stakeholders, from the retail pharmacies looking to innovate and drive profitability to the healthcare professionals seeking affordable medication solutions for their patients so they can adhere to their treatment plans,” said Wendy Barnes, Chief Executive Officer and President of GoodRx. “I’m confident Aaron and Scott are the right leaders to help us deliver against these key business priorities and accelerate our efforts to fill gaps in insurance coverage and reduce friction across the healthcare system.”

About GoodRx

GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $85 billion on the cost of their medications.

​GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

GoodRx Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, the statements regarding anticipated future performance of the Company and expected benefits to the Company related to these executive appointments. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250317163984/en/